[Basic studies on the lipiodolization of miriplatin in combination with CDDP].
Platinum release and initial hepatic toxicity of a formulation containing both miriplatin (MPT) and cisplatin (CDDP), prepared to improve the weak initial effect of MPT-Lipiodol (LPD) suspension, were evaluated. No difference in platinum release from CDDP was found between CDDP-LPD and MPT·CDDP-LPD, which suggested that platinum release was not affected by the viscosity of MPT-LPD. On the day following administration into rat portal vein, drugs suspended in LPD increased liver function values, and these values returned to the previous levels 3 days after administration. Both the CDDP-LPD and MPT· CDDP-LPD groups showed higher liver function values than the MPT-LPD group, and there was little difference in liver function values between the CDDP-LPD and MPT·CDDP-LPD groups. Thus, MPT·CDDP-LPD retains the characteristics of MPTLPD and CDDP-LPD without reducing the effects of either drug or enhancing their side effects.
Faculty of Pharmaceutical Sciences, Kobe Gakuin University.
Shuichi
S
Kishimoto
Shingo
S
Adachi
Aya
A
Masui
Ryosuke
R
Suzuki
Toru
T
Beppu
Shoji
S
Fukushima
D000818:Animals; D002945:Cisplatin / Q000008:administration & dosage / Q000737:chemistry / Q000633:toxicity*; D005260:Female; D007262:Infusions, Intravenous; D008055:Lipids / Q000737:chemistry*; D008099:Liver / Q000187:drug effects* / Q000502:physiology; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000737:chemistry / Q000633:toxicity*; D017207:Rats, Sprague-Dawley
D008055:Lipids; D009944:Organoplatinum Compounds; C406530:miriplatin; D002945:Cisplatin